Detalhe da pesquisa
1.
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Breast Cancer Res Treat
; 149(3): 669-80, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25663547
2.
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Breast Cancer Res Treat
; 141(3): 397-408, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24091768
3.
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Breast Cancer Res
; 11(5): R77, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19874578
4.
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Mol Cancer Ther
; 12(4): 509-19, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23395886
5.
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Mol Cancer Ther
; 12(6): 890-900, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23493311
6.
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
J Thorac Oncol
; 8(3): 270-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23399957
7.
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Anticancer Res
; 33(8): 2997-3004, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23898052
8.
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Mol Cancer Ther
; 11(9): 1978-87, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22761403
9.
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Clin Cancer Res
; 16(5): 1509-19, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20179222